Suppr超能文献

p85α 中的体细胞突变通过 IA 类 PI3K 激活促进肿瘤发生。

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

作者信息

Jaiswal Bijay S, Janakiraman Vasantharajan, Kljavin Noelyn M, Chaudhuri Subhra, Stern Howard M, Wang Weiru, Kan Zhengyan, Dbouk Hashem A, Peters Brock A, Waring Paul, Dela Vega Trisha, Kenski Denise M, Bowman Krista K, Lorenzo Maria, Li Hong, Wu Jiansheng, Modrusan Zora, Stinson Jeremy, Eby Michael, Yue Peng, Kaminker Josh S, de Sauvage Frederic J, Backer Jonathan M, Seshagiri Somasekar

机构信息

Department of Molecular Biology, Genentech Inc., South San Francisco, CA 94080, USA.

出版信息

Cancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.

Abstract

Members of the mammalian phosphoinositide-3-OH kinase (PI3K) family of proteins are critical regulators of various cellular process including cell survival, growth, proliferation, and motility. Oncogenic activating mutations in the p110alpha catalytic subunit of the heterodimeric p110/p85 PI3K enzyme are frequent in human cancers. Here we show the presence of frequent mutations in p85alpha in colon cancer, a majority of which occurs in the inter-Src homology-2 (iSH2) domain. These mutations uncouple and retain p85alpha's p110-stabilizing activity, while abrogating its p110-inhibitory activity. The p85alpha mutants promote cell survival, AKT activation, anchorage-independent cell growth, and oncogenesis in a p110-dependent manner.

摘要

哺乳动物磷酸肌醇-3-羟基激酶(PI3K)蛋白家族成员是多种细胞过程的关键调节因子,包括细胞存活、生长、增殖和运动。异二聚体p110/p85 PI3K酶的p110α催化亚基中的致癌激活突变在人类癌症中很常见。在这里,我们展示了结肠癌中p85α存在频繁突变,其中大多数发生在Src同源结构域2(iSH2)之间。这些突变使p85α的p110稳定活性解偶联并保留,同时消除其p110抑制活性。p85α突变体以p110依赖的方式促进细胞存活、AKT激活、不依赖贴壁的细胞生长和肿瘤发生。

相似文献

1
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Cancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.
2
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15547-52. doi: 10.1073/pnas.1009652107. Epub 2010 Aug 16.
3
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Cell Cycle. 2008 May 1;7(9):1151-6. doi: 10.4161/cc.7.9.5817. Epub 2008 Feb 27.
4
A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19897-902. doi: 10.1073/pnas.1008739107. Epub 2010 Oct 28.
6
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Science. 2007 Jul 13;317(5835):239-42. doi: 10.1126/science.1135394.
8
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
Proc Natl Acad Sci U S A. 2007 May 8;104(19):7809-14. doi: 10.1073/pnas.0700373104. Epub 2007 Apr 30.
10
Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
J Biol Chem. 2005 Jul 29;280(30):27850-5. doi: 10.1074/jbc.M506005200. Epub 2005 Jun 2.

引用本文的文献

1
Cancer-Associated Genetic Aberrations and Precision Medicine.
Int J Med Sci. 2025 Jun 12;22(12):2932-2943. doi: 10.7150/ijms.109506. eCollection 2025.
3
High Frequency of Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations.
Cancers (Basel). 2025 Jan 15;17(2):269. doi: 10.3390/cancers17020269.
4
Molecular Basis of Oncogenic PI3K Proteins.
Cancers (Basel). 2024 Dec 30;17(1):77. doi: 10.3390/cancers17010077.
8
Divergent roles of the regulatory subunits of class IA PI3K.
Front Endocrinol (Lausanne). 2024 Jan 22;14:1152579. doi: 10.3389/fendo.2023.1152579. eCollection 2023.
9
Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
Breast Cancer Res Treat. 2024 Apr;204(2):407-414. doi: 10.1007/s10549-023-07196-4. Epub 2023 Dec 28.

本文引用的文献

1
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.
Science. 2009 Mar 27;323(5922):1747-50. doi: 10.1126/science.1163040. Epub 2009 Feb 26.
2
Class I PI3K in oncogenic cellular transformation.
Oncogene. 2008 Sep 18;27(41):5486-96. doi: 10.1038/onc.2008.244.
3
PTEN: a new guardian of the genome.
Oncogene. 2008 Sep 18;27(41):5443-53. doi: 10.1038/onc.2008.241.
4
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4.
5
An integrated genomic analysis of human glioblastoma multiforme.
Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.
6
Structural comparisons of class I phosphoinositide 3-kinases.
Nat Rev Cancer. 2008 Sep;8(9):665-9. doi: 10.1038/nrc2443.
7
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Cell Cycle. 2008 May 1;7(9):1151-6. doi: 10.4161/cc.7.9.5817. Epub 2008 Feb 27.
8
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Oncogene. 2008 Jul 3;27(29):4096-106. doi: 10.1038/onc.2008.40. Epub 2008 Mar 3.
10
A membrane capture assay for lipid kinase activity.
Nat Protoc. 2007;2(10):2459-66. doi: 10.1038/nprot.2007.361.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验